Mysthera Therapeutics
- Company typePrivate
- Founded2023
- HeadquartersBasel, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Mysthera Therapeutics firmographics
Firmographics- Name
- Mysthera Therapeutics
- Legal name
- Mysthera Therapeutics AG
- Website
- https://mystheratx.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Mysthera Therapeutics industry classification
Industry- Product category
- Autoimmune Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Mysthera Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Mysthera Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Drug Development and Commercialization: Pre-revenue company developing novel oral therapeutics for autoimmune diseases. Revenue model will be based on pharmaceutical product sales following successful clinical development and regulatory approval.
Mysthera Therapeutics product offering
Product offeringCore offering
Mysthera Therapeutics is a Swiss biotech company developing first-in-class pan-PIM kinase inhibitors as oral therapeutics for autoimmune diseases. The company is at the pre-clinical stage, focused on modulating immune cell functions through its proprietary pan-PIM kinase inhibitor pipeline.
Product overview
Mysthera Therapeutics is a Swiss biotech company developing oral therapeutics for autoimmune diseases. The company's pipeline consists of pre-clinical stage, pan-PIM kinase inhibitors designed to modulate immune cell functions. The company launched with $3.5 million in seed funding from Forty51 Ventures to advance these pre-clinical drug candidates targeting PIM kinase.
Differentiator
Problem solved
Functional benefit
Products and services
- Pan-PIM Kinase Inhibitor Pipeline Pre-clinical stage pan-PIM kinase inhibitors designed to modulate immune cell functions involved in autoimmune conditions. These oral therapeutic candidates target unmet needs in autoimmune disease treatment.
Companies that use Mysthera Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Mysthera Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Mysthera Therapeutics partnerships and signals
Strategic signalScale indicators2 records
Recent moves3 records
Expansion highlights2 records
Mysthera Therapeutics competitors and assessment
Company assessmentDirect peers
- Nimbus Therapeutics: Computationally-driven small-molecule biotech with autoimmune and metabolic programs. Comparable to Mysthera as a small-molecule immunology company pursuing differentiated mechanisms in well-validated targets.
- Dice Therapeutics: Pre-clinical and clinical-stage biotech developing oral small-molecule therapeutics for autoimmune diseases (e.g., IL-17 inhibitors). Highly comparable to Mysthera in modality (oral) and indication focus (autoimmune); acquired by Eli Lilly in 2023, illustrating large-pharma appetite for this profile.
- Morphic Therapeutic: Developer of oral integrin inhibitors for autoimmune diseases (lead asset etrasimod in ulcerative colitis, Crohn's). Directly comparable as an oral small-molecule autoimmune company; acquired by Eli Lilly in 2024.
- Alpine Immune Sciences: Clinical-stage autoimmune and inflammatory disease company (e.g., povetacicept). Comparable as an autoimmune-focused biotech acquired by Vertex in 2024, signaling continued pharma interest in differentiated autoimmune mechanisms.
- Arcutis Biotherapeutics: Late-stage dermatology/autoimmune biotech focused on topical and oral therapies (e.g., roflumilast). Comparable in modality mix and autoimmune indication focus, with proven commercial-stage execution.
- Pliant Therapeutics: Clinical-stage biotech developing small-molecule therapeutics for fibrotic and autoimmune-related diseases. Comparable small-molecule immunology profile and indication overlap (immune dysregulation).
Emerging players
- Cartesian Therapeutics: Clinical-stage biotech developing RNA cell therapies for autoimmune diseases. Comparable autoimmune indication focus but uses a different therapeutic modality (cell therapy) versus Mysthera's oral small molecules.
- Janux Therapeutics: Clinical-stage biotech developing T cell engager therapies for autoimmune diseases. Comparable indication focus, though differentiated modality (biologic T cell engagers vs. Mysthera's small-molecule kinase inhibitors).
Broad incumbents
- AnaptysBio: Clinical-stage immunology biotech with multiple autoimmune and inflammatory pipeline assets and royalty interests. Comparable indication focus (autoimmune) with broader portfolio scope than Mysthera.
- Kymera Therapeutics: Clinical-stage biotech developing targeted protein degradation (TPD) therapies in immunology and oncology. Comparable in immunology focus and kinase-pathway adjacent biology, though broader in platform scope.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Mysthera Therapeutics social profiles
Digital presenceMysthera Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mysthera Therapeutics leadership team
Management profileNumber of profiles
Mysthera Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mysthera Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mysthera Therapeutics
What does Mysthera Therapeutics do?
Mysthera Therapeutics is a Swiss biotech company developing first-in-class pan-PIM kinase inhibitors as oral therapeutics for autoimmune diseases. The company is at the pre-clinical stage, focused on modulating immune cell functions through its proprietary pan-PIM kinase inhibitor pipeline.
Is Mysthera Therapeutics a public or private company?
Mysthera Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mysthera Therapeutics founded?
Mysthera Therapeutics was founded in 2023. It employs 1 to 10 people.
Where is Mysthera Therapeutics based?
Mysthera Therapeutics is headquartered in Basel, Switzerland, in the Europe region.
How does Mysthera Therapeutics make money?
One revenue line is on record: drug Development and Commercialization.
Who are Mysthera Therapeutics's main competitors?
Direct peers on record are Nimbus Therapeutics, Dice Therapeutics, Morphic Therapeutic, Alpine Immune Sciences, Arcutis Biotherapeutics and Pliant Therapeutics. Emerging players are Cartesian Therapeutics and Janux Therapeutics. Broad incumbents are AnaptysBio and Kymera Therapeutics.
Does Mysthera Therapeutics have an API?
No public API is recorded for Mysthera Therapeutics.
What industry is Mysthera Therapeutics in?
Mysthera Therapeutics's product category is Autoimmune Disease Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 541714.